Speakers
Description
Radioisotopes such as ²¹³Bi, ²²³Ra, ²²⁵Ac, and ²²⁷Th are alpha emitters and are regarded as among the most promising candidates for targeted cancer radiotherapy, owing to the high linear energy transfer, ~100 keV/μm, and their short path length in biological tissue, typically 50–100 μm. Recently, IRIS initiated a project to develop ²²⁵Ac production by irradiating ²³²ThO₂ targets with protons in the energy range of 40–70 MeV.
Based on theoretical estimates, irradiation of a 3-mm-thick ²³²ThO₂ target with 70 MeV protons at a beam current of approximately 100 μA for two days is expected to produce about 100 mCi of ²²⁵Ac, which could be used for preclinical evaluation of radiopharmaceuticals.
In addition, the ISOL facility, combined with the operation of the 70 MeV cyclotron, could provide several high-purity radioisotopes using a high-resolution separator. The ISOL project reached a major milestone in August 2024, when the first RI beam was extracted from the cyclotron and accelerated to 16 MeV/u by the superconducting LINAC at IRIS. This talk will present a brief overview of recent research activities related to the ISOL system and the 70 MeV cyclotron at IRIS.
Funding Agency
This work was supported by INNOPOLIS grant funded (RS-2026-25506728) and by National Research Foundation (NRF) grant (TOPTIER, RS-2024-00436392) by the Korea government of Ministry of Science and ICT
| I have read and accept the Privacy Policy Statement | Yes |
|---|